# A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

> **NCT07082725** · PHASE3 · RECRUITING · sponsor: **Azafaros A.G.** · enrollment: 72 (estimated)

## Conditions studied

- Niemann-Pick Type C Disease

## Interventions

- **DRUG:** Nizubaglustat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07082725
- **Lead sponsor:** Azafaros A.G.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-11-04
- **Final completion:** 2027-11-04
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082725, "A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07082725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*